Ovarian Cancer Conference – ESGO Gynae-Oncology Guidelines

ESGO-ESMO Consensus Conference on Ovarian Cancer


In cooperation with the European Society of Medical Oncology (ESMO) and encompassing the existing ESGO Recommendations for Ovarian Cancer Surgery, ESGO has recently started to develop the guidelines for the management of ovarian cancer.


The consensus conference on ovarian cancer management initiated by the European Society of Gynaecological Oncology (ESGO) together with the European Society of Medical Oncology (ESMO) took place in April 2018 in Milan, Italy. The conference included input of 42 top European and overseas key opinion leaders in the area, from 20 countries.
The participants worked in four working groups (Pathology & Molecular Biology, Early Stage & Borderline, Advanced Stage, and Recurrent Disease), splitting the heavy scientific agenda into 20 pertinent questions which are available bellow.

The outcomes of the consensus conference are expected to be published in May 2019. The first public presentations took place at the ESGO State of the Art Conference in Lyon (October 4-6, 2018) and at the ESMO Congress in Munich (October 19-23, 2018).

The webcast of the session presenting the outcomes of the consensus conference are available for all ESGO members and subscribers on the ESGO eAcademy. Click here to view.

Pertinent questions of the consensus conference:

  1. How to determine the site of origin of extrauterine high grade serous carcinoma?
  2. How to identify tumours that will respond to targeted therapies, including PARP inhibitors and immune checkpoint inhibitors?
  3. How to identify patients with acquired/intrinsic resistance to chemotherapy?
  4. Can we develop accurate and sensitive circulating and tissue biomarkers both of response and relapse?
  5. What are the morphological criteria useful in separating borderline from invasive ovarian neoplasia?
  6. Are there exceptions to the standard surgical management for early stage ovarian carcinoma?
  7. What are the limits of fertility sparing surgery (cancer & BOT)?
  8. Should all stage I carcinoma receive adjuvant chemotherapy and if not which ones?
  9. Are non-serous BOT managed according to the same standard as serous BOT?
  10. How should serous BOT with extraovarian implant be managed?
  11. How to select patients for primary debulking surgery or neoadjuvant chemotherapy?
  12. What is the current role of bevacizumab in first-line treatment?
  13. Should we use weekly regimens in first-line?
  14. Is there a place for intraperitoneal chemotherapy and HIPEC?
  15. Is the standard of management of non high grade serous epithelial ovarian carcinoma different?
  16. What is a reasonable monitoring and follow up strategy following treatment of ovarian cancer?
  17. What is the place of surgery for recurrent disease?
  18. How should molecularly targeted therapy be integrated into the management of recurrent ovarian cancer´?
  19. What defines platinum resistance and how does that influence subsequent treatment?
  20. How long should maintenance therapy be continued in recurrent disease

You May Also Like


Advanced Ovarian Cancer Surgery

Quality Indicators


Read More


Endometrial Cancer Guidelines

Free Download


Read More


Cervical Cancer Management

Latest Algorithms


Read More


Vulvar Cancer Guidelines

Guidelines and QI


Read More